Louisiana State Employees Retirement System raised its position in shares of Repligen Corporation (NASDAQ:RGEN) by 9.4% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 15,100 shares of the biotechnology company’s stock after buying an additional 1,300 shares during the period. Louisiana State Employees Retirement System’s holdings in Repligen Corporation were worth $626,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. BlackRock Inc. boosted its position in Repligen Corporation by 143,196.5% in the first quarter. BlackRock Inc. now owns 4,664,302 shares of the biotechnology company’s stock worth $164,187,000 after buying an additional 4,661,047 shares in the last quarter. TimesSquare Capital Management LLC boosted its position in Repligen Corporation by 35.1% in the first quarter. TimesSquare Capital Management LLC now owns 1,970,725 shares of the biotechnology company’s stock worth $69,370,000 after buying an additional 512,300 shares in the last quarter. Norges Bank acquired a new position in Repligen Corporation during the fourth quarter worth about $8,527,000. Macquarie Group Ltd. boosted its position in Repligen Corporation by 481.1% in the fourth quarter. Macquarie Group Ltd. now owns 319,668 shares of the biotechnology company’s stock worth $9,852,000 after buying an additional 264,659 shares in the last quarter. Finally, MARSHALL WACE ASIA Ltd acquired a new position in Repligen Corporation during the first quarter worth about $9,006,000. 99.02% of the stock is owned by institutional investors and hedge funds.

Shares of Repligen Corporation (NASDAQ RGEN) traded up 1.7120% during mid-day trading on Tuesday, reaching $43.2581. The company’s stock had a trading volume of 68,699 shares. The firm has a market cap of $1.47 billion, a PE ratio of 114.1375 and a beta of 1.30. Repligen Corporation has a 12 month low of $26.16 and a 12 month high of $46.81. The company has a 50-day moving average of $41.28 and a 200-day moving average of $36.10.

Repligen Corporation (NASDAQ:RGEN) last announced its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported $0.20 EPS for the quarter, beating the Zacks’ consensus estimate of $0.15 by $0.05. Repligen Corporation had a return on equity of 9.90% and a net margin of 15.61%. The firm had revenue of $32.40 million for the quarter, compared to analyst estimates of $31.72 million. During the same period last year, the firm posted $0.16 earnings per share. The business’s revenue for the quarter was up 11.0% on a year-over-year basis. On average, analysts predict that Repligen Corporation will post $0.58 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Repligen Corporation (NASDAQ:RGEN) Shares Bought by Louisiana State Employees Retirement System” was originally posted by Daily Political and is the property of of Daily Political. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this news story can be viewed at https://www.dailypolitical.com/2017/08/08/repligen-corporation-nasdaqrgen-shares-bought-by-louisiana-state-employees-retirement-system.html.

RGEN has been the subject of a number of research analyst reports. Janney Montgomery Scott lifted their price target on Repligen Corporation from $42.00 to $47.00 in a report on Friday, June 23rd. BidaskClub raised Repligen Corporation from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 24th. Jefferies Group LLC reissued a “hold” rating and set a $40.00 price objective (up from $33.00) on shares of Repligen Corporation in a report on Wednesday, June 28th. Zacks Investment Research raised Repligen Corporation from a “hold” rating to a “buy” rating and set a $43.00 price objective for the company in a report on Thursday, May 11th. Finally, William Blair began coverage on Repligen Corporation in a report on Friday, July 21st. They set an “outperform” rating for the company. Three analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $41.20.

About Repligen Corporation

Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.

Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Corporation (NASDAQ:RGEN).

Institutional Ownership by Quarter for Repligen Corporation (NASDAQ:RGEN)

Receive News & Ratings for Repligen Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Corporation and related companies with MarketBeat.com's FREE daily email newsletter.